Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600112 | 0.85 | TDP1 (0.51) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL10593672 | 0.80 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1HTTLMNA | |
| SCHEMBL2881517 | 0.80 | MEN1 (0.49) | MEN1KMT2AKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL346667 | 0.79 | HTT (0.59) | MEN1KMT2AKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL6668957 | 0.78 | L3MBTL1 (0.50) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29261850 | 0.78 | HTT (0.58) | MEN1KMT2AKEAP1NFE2L2ALDH1A1 | |
| Iodide SCHEMBL3347426 | 0.78 | HTT (0.58) | MEN1KMT2AKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL4126086 | 0.77 | MEN1 (0.60) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18179825 | 0.77 | MEN1 (0.60) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL9852204 | 0.77 | MEN1 (0.60) | MEN1KMT2AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | claimed |
| CN-102120741-A | Production method of an optically active compound | MITSUBISHI TANABE PHARMA CORP | 2011-07-13 | — | — | CN | disclosed |
| CN-102050820-A | Preparation method of compound with optical activity | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| US-20060019940-A1 | Novel benzoxazocines and their therapeutic use | SOSEI R&D LTD. (GB) | 2006-01-26 | — | — | US | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| EP-1140515-B1 | HEAT SENSITIVE RECORDING MATERIAL | CIBA SC HOLDING AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6624117-B1 | Heat sensitive recording material | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-09-23 | — | — | US | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| US-4006128-A | CELLULOSE ACETATES, VINYL POLYMERS, POLYOLEFINS, POLYESTERS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019940-A1 | Novel benzoxazocines and their therapeutic use | HTR4, OPRM1, GRM4 | MEN1 1576/4885KMT2A 1143/4885KEAP1 1238/4885 |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | MEN1 3387/4885KMT2A 3750/4885KEAP1 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.